Feb 19, 2026The Next Protein-Design Leap May Not Be Open to Everyone
The AlphaFold story used to feel like a public-science triumph: a hard biological problem became easier because a powerful model was released widely enough for researchers to build on it. This new Nature report points to a more complicated next chapter. Isomorphic Labs, the drug-discovery company spun out of DeepMind, says it has built a model that goes beyond AlphaFold 3 for drug-design work, but the system itself is being kept inside the company. That distinction is the heart of the story. A model that can better reason about proteins, small molecules, and the physical interactions between them could help researchers imagine drug candidates faster. But if the best version is proprietary, outside scientists cannot fully test it, compare it, reproduce it, or learn how to reach similar performance. The advance may be real and still leave the wider field guessing.
AI Has Started Making Drug-Like Antibodies. The Hard Part Is Knowing What That Means.
Jan 6, 2026
RFpeptides Shows What AI Can Do Before a Peptide Becomes a Drug
Protein-Design AI Is Moving From Specialist Labs to Everyday Biology
The Cancer Question Around GLP-1s Is Promising, but Still Early
Jun 19, 2026
